Techne Corp. (NASDAQ:TECH) shares dropped 0.4% on Friday . The stock traded as low as $114.43 and last traded at $114.73, with a volume of 87,627 shares. The stock had previously closed at $115.17.

TECH has been the subject of several recent analyst reports. Zacks Investment Research cut Techne Corp. from a “hold” rating to a “sell” rating in a research note on Friday, April 15th. TheStreet upgraded Techne Corp. from a “hold” rating to a “buy” rating in a research note on Thursday, March 10th. Leerink Swann restated a “hold” rating and issued a $105.00 price target on shares of Techne Corp. in a research note on Thursday, May 5th. Finally, Janney Montgomery Scott upgraded Techne Corp. from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $100.00 to $118.00 in a research note on Tuesday, May 3rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Techne Corp. has an average rating of “Buy” and an average target price of $109.60.

The company has a market cap of $4.29 billion and a price-to-earnings ratio of 40.99. The stock’s 50 day moving average price is $110.64 and its 200 day moving average price is $95.83.

Techne Corp. (NASDAQ:TECH) last released its quarterly earnings data on Tuesday, May 3rd. The company reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.12. The company had revenue of $131 million for the quarter, compared to analysts’ expectations of $122.65 million. The business’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.88 EPS. Analysts predict that Techne Corp. will post $3.64 EPS for the current year.

In related news, Director Roger C. Lucas sold 500 shares of Techne Corp. stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $100.24, for a total value of $50,120.00. Following the completion of the transaction, the director now owns 3,915 shares in the company, valued at approximately $392,439.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Charles A. Dinarello sold 5,000 shares of Techne Corp. stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $101.91, for a total value of $509,550.00. Following the completion of the transaction, the director now owns 6,559 shares of the company’s stock, valued at approximately $668,427.69. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in the stock. Suntrust Banks Inc. raised its position in shares of Techne Corp. by 35.9% in the fourth quarter. Suntrust Banks Inc. now owns 12,684 shares of the company’s stock valued at $1,141,000 after buying an additional 3,351 shares in the last quarter. BHF Kleinwort Benson Group S.A. boosted its stake in Techne Corp. by 65.8% in the fourth quarter. BHF Kleinwort Benson Group S.A. now owns 22,995 shares of the company’s stock valued at $2,070,000 after buying an additional 9,130 shares during the last quarter. Liberty Mutual Group Asset Management Inc. boosted its stake in Techne Corp. by 51.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 23,950 shares of the company’s stock valued at $2,155,000 after buying an additional 8,128 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in Techne Corp. by 3.9% in the fourth quarter. Mutual of America Capital Management LLC now owns 25,553 shares of the company’s stock valued at $2,300,000 after buying an additional 966 shares during the last quarter. Finally, TD Asset Management Inc. boosted its stake in Techne Corp. by 306.9% in the fourth quarter. TD Asset Management Inc. now owns 29,300 shares of the company’s stock valued at $2,637,000 after buying an additional 22,100 shares during the last quarter.

Bio-Techne Corporation (Bio-Techne), formerly Techne Corporation, develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products around the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.